Scottsdale 7/29/2010 1:41:23 AM
Sanguine Corp. (SGUI.OB) Receives Notable Purchase Order from Virginia Commonwealth University
QualityStocks would like to highlight Sanguine Corp. (OTCBB: SGUI), a bio-pharmaceutical company developing products for use in biomedical and medical device applications.
In the company’s news yesterday,
Sanguine Corp. announced a “significant” purchase order from Virginia Commonwealth University (VCU) for PHER-O2, Sanguine’s ultra-oxygen carrying perfluorocarbon-based product. Shares of SGUI soared 30 percent to $.39 on word of the purchase.
VCU is nationally recognized for its research in groundbreaking work using perfluorocarbons (PFCs); applications of perfluorocarbons include eye surgery, imaging, liquid ventilation, artificial blood and treatment of decompression sickness, as well as various other non-medical applications.
VCU contracts are part of several current U.S. Federal Government funded projects, and are backed by millions of dollars in aggregate project funding; additional projects are currently in various phases to obtain grant funding. Sanguine said it will serve as the exclusive supplier to these projects, and that it plans to negotiate partnership in the near future.
Frank Marra, a Sanguine spokesperson, said the partnership with VCU reflects Sanguine’s efforts to strengthen and quicken its growth, and said he anticipates the collaborative research of both entities to open the door for treatment methods.
“As a result of our approach, begun last year, to accelerate our growth through strategic and targeted development alliances, we are extremely excited about our relationship with VCU. Under Dr. Bruce Spiess’ leadership, VCURES’ team is considered to be at the forefront of the world’s experts in research and development of innovative and novel pefluorocarbon-based solutions to a number of critical diseases and injuries. The research to be conducted with the PHER-O2 is expected to significantly advance the market acceptance of PFCs and lead to many important products and treatment methods for critical diseases and injuries,” Marra stated in the press release.
Researchers at the VCU Reanimation Engineering Shock Center (VCURES) are conducting pre-clinical trials, including: Neurological Events (Traumatic Brain Injury (TBI), Traumatic Spinal Cord Injury, Stroke); Organ Preservation (Cardioplegia, Heart Transplant, Liver Preservation, Kidney Transplant, Islet Cell Preservation); and Intravenous Enhanced Oxygen Delivery (Multifunctional Resuscitation Solutions, Sickle Cell Crisis, Carbon Monoxide Poisoning, Cardiopulmonary Resuscitation).
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
